<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-11-13</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-11-13</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>90</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>4</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ“° å…¬ä¼—å·</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
è…¾è®¯å¼€å‘<strong>æ–°å‹é¢„è®­ç»ƒå¤§å‹ç”Ÿæˆæ¨¡å‹</strong>ï¼Œå®ç°å•ç»†èƒè½¬å½•ç»„åˆ°è›‹ç™½è´¨ç»„çš„ç¿»è¯‘ï¼›å± å‘¦å‘¦å›¢é˜Ÿåˆ©ç”¨<strong>å•ç»†èƒæµ‹åº</strong>å‘ç°<strong>é’è’¿ç´ å…ç–«è°ƒèŠ‚æ–°æœºåˆ¶</strong>ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒè§£æ</strong>ï¼šèšç„¦å®«é¢ˆç™Œã€è‚ç™Œã€é£Ÿç®¡é³ç™Œç­‰ï¼Œç»˜åˆ¶å…¨æ™¯å›¾è°±ã€‚<br />
*   <strong>æ°¨åŸºé…¸ä»£è°¢ä¸è‚¿ç˜¤å…ç–«</strong>ï¼šæ·±å…¥æ¢ç´¢ç»„æ°¨é…¸ã€è°·æ°¨é…°èƒºä»£è°¢å¯¹è‚¿ç˜¤å…ç–«æŠ‘åˆ¶åŠæ²»ç–—ç–—æ•ˆçš„å½±å“ã€‚<br />
*   <strong>ç™Œç—‡è€è¯ä¸æ²»ç–—ç­–ç•¥</strong>ï¼šç ”ç©¶ERKæŠ‘åˆ¶å‰‚å…‹æœè€è¯ï¼Œä»¥åŠé¥®é£Ÿæ¨¡å¼ä¸è¯ç‰©è”ç”¨ã€mRNAç–«è‹—ç­‰æ–°ç–—æ³•ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>å•ç»†èƒä¸ç©ºé—´è½¬å½•ç»„å­¦</strong>ï¼šå¹¿æ³›åº”ç”¨äºç»˜åˆ¶è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒã€å¾®ç”Ÿç‰©ç»„ä¸å…ç–«äº’ä½œã€‚<br />
*   <strong>å¤šç»„å­¦æ•´åˆä¸æœºå™¨å­¦ä¹ </strong>ï¼šç»“åˆç™¾ç§æœºå™¨å­¦ä¹ ç®—æ³•ã€Scissorç­‰è¿›è¡Œæ·±å…¥åˆ†æã€‚<br />
*   <strong>è›‹ç™½è´¨ç»„å­¦å›¾è°±æ„å»º</strong>ï¼šè§£æäººç±»æ³›ç–¾ç—…è¡€æ¶²è›‹ç™½è´¨ç»„ã€‚</p>
<h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
CDK4/6æŠ‘åˆ¶å‰‚Palbociclibè”åˆVenetoclaxåœ¨æ€¥æ€§é«“ç³»ç™½è¡€ç—…ä¸­å±•ç°å‡ºå…‹æœè€è¯æœºåˆ¶çš„æ½œåŠ›ï¼Œå¹¶ä¼˜äºå•è¯æ²»ç–—ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- ç™½è¡€ç—…æ²»ç–—ï¼šæ¢ç´¢CDK4/6æŠ‘åˆ¶å‰‚è”åˆVenetoclaxæ²»ç–—AMLçš„ç­–ç•¥ï¼›ç ”ç©¶AKAP95åœ¨MLL-èåˆé©±åŠ¨ç™½è¡€ç—…è½¬å½•è°ƒæ§ä¸­çš„ä½œç”¨ã€‚<br />
- ç™Œç—‡åˆ†å­æœºåˆ¶ï¼šæ­ç¤ºPTBP1åœ¨ç™½è¡€ç—…ç»†èƒå­˜æ´»ä¸­çš„ä½œç”¨ï¼›ç ”ç©¶Plagl1å’ŒLrrc58è°ƒæ§microRNAé™è§£ä¸å“ºä¹³åŠ¨ç‰©ä½“å‹å¤§å°çš„å…³ç³»ï¼›æ¢ç©¶L-2-hydroxyglutarateå¯¹è‚¾ç™Œm6A RNAç”²åŸºåŒ–çš„å½±å“ï¼›é˜æ˜METTL3ä»‹å¯¼çš„m6A RNAç”²åŸºåŒ–å¯¹äººæ»‹å…»å±‚å¹²ç»†èƒè‡ªæˆ‘æ›´æ–°å’Œç»†èƒèº«ä»½ç»´æŒçš„é‡è¦æ€§ã€‚<br />
- ç»†èƒå‘è‚²ä¸å†ç”Ÿï¼šè§£æè¡°è€å¯¹éª¨å†ç”Ÿä¸­éª¨è†œç¥–ç»†èƒå’Œå…ç–«å¾®ç¯å¢ƒçš„å½±å“ï¼›ç ”ç©¶INHBAåœ¨ç»µç¾Šé¢—ç²’ç»†èƒä¸­çš„ä½œç”¨ã€‚<br />
- è¡¨è§‚é—ä¼ å­¦ï¼šå¼€å‘å¯ç¼–ç¨‹æŸ“è‰²è´¨ä¹™é…°åŒ–CRISPR/Casè¡¨è§‚é—ä¼ ç¼–è¾‘å™¨ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- ç»“åˆRNA-Seqã€CRISPR Screenã€ChIP-Seqã€CUT&amp;Tagã€Perturb-seqã€PRO-Seqã€CLIP-Seqã€scRNA-seqã€Long Readã€Methylation profilingç­‰å¤šç§é«˜é€šé‡æµ‹åºæŠ€æœ¯ï¼Œå…¨é¢è§£æåŸºå› è°ƒæ§ä¸ç–¾ç—…æœºåˆ¶ã€‚<br />
- æ¢ç´¢äº† phase separation (ç›¸åˆ†ç¦») åœ¨è½¬å½•è°ƒæ§ä¸­çš„ä½œç”¨ã€‚</p>
<h3>ğŸ”¬ æœŸåˆŠæ–‡ç« </h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
USP20é©±åŠ¨çš„èƒ†å›ºé†‡ä»£è°¢ä¸ç‚ç—‡ä¿¡å·ä¼ å¯¼åœ¨èƒ°è…ºç™Œæ¶æ€§è¿›å±•åŠåŸºè´¨å…±åŒè¿›åŒ–ä¸­çš„å…³é”®ä½œç”¨è¢«æ­ç¤ºï¼Œä¸ºé¶å‘æ²»ç–—æä¾›äº†æ–°æ€è·¯ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è¯„ä¼°å¶é…¸å—ä½“Î±ï¼ˆFRÎ±ï¼‰ç–«è‹—åœ¨ä¸‰é˜´æ€§ä¹³è…ºç™Œä¸­çš„å®‰å…¨æ€§åŠå…ç–«åŸæ€§ï¼Œæ¢ç´¢ç®€åŒ–ç–«è‹—ç­–ç•¥ã€‚<br />
- é˜æ˜è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒäº§ç”ŸPGE2å¯¼è‡´CD8+ Tç»†èƒè€—ç«­ï¼Œé©±åŠ¨å¾®å«æ˜Ÿç¨³å®šç»“ç›´è‚ ç™Œå¯¹PD-L1é˜»æ–­æ²»ç–—è€è¯çš„æœºåˆ¶ã€‚<br />
- å‘ç°æ–°å‹ç¯çŠ¶RNAç¼–ç è›‹ç™½cPFKFB4ï¼Œå…¶å¢å¼ºè‘¡è„ç³–ä»£è°¢é‡ç¼–ç¨‹ï¼Œä¿ƒè¿›ç¼ºæ°§ä¸‹èƒ°è…ºç™Œè¿›å±•ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- æ•´åˆå¤šç»„å­¦æ•°æ®ï¼ˆä¸´åºŠé˜Ÿåˆ—ã€æ‚£è€…æ¥æºç±»å™¨å®˜ã€æœ¬åœŸæ¨¡å‹ï¼‰è§£æèƒ°è…ºç™Œç‚ç—‡ä¸ä»£è°¢çš„ä¸²æ‰°ã€‚<br />
- è¡¨å¾å¾®å«æ˜Ÿç¨³å®šå’Œä¸ç¨³å®šç»“ç›´è‚ ç™Œæ¨¡å‹çš„å…ç–«è°±ï¼Œæ·±å…¥ç†è§£å…ç–«æ²»ç–—è€è¯æœºåˆ¶ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹å…ç–«ç‹¬ç«‹ç»†èŒç–—æ³•AUNæˆåŠŸæ‘§æ¯è‚¿ç˜¤ï¼›å¾®å‹æ¤å…¥ç‰©TAR-200åœ¨82%çš„è†€èƒ±ç™Œæ‚£è€…ä¸­æ¶ˆç­è‚¿ç˜¤ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- <strong>ç™Œç—‡æ²»ç–—</strong>ï¼šå¼€å‘ç»†èŒç–—æ³•ã€è¯ç‰©é‡Šæ”¾æ¤å…¥ç‰©ã€æ”¾å°„æ€§åŒä½ç´ ç–—æ³•ï¼Œä»¥åŠé¶å‘å…³é”®é…¶æŠ‘åˆ¶ç™Œç»†èƒç”Ÿé•¿ã€‚<br />
- <strong>é˜¿å°”èŒ¨æµ·é»˜ç—…</strong>ï¼šæ¢ç´¢å¾®å°æŠ—ä½“å’Œå¤§è„‘å…ç–«ç»†èƒå¯¹ç–¾ç—…çš„æ²»ç–—æ½œåŠ›ï¼Œå¹¶æ­ç¤ºæ¸…é™¤è„‘éƒ¨æ–‘å—å¹¶éæ²»æ„ˆçš„å…¨éƒ¨ã€‚<br />
- <strong>ç–¾ç—…è¯Šæ–­ä¸ç›‘æµ‹</strong>ï¼šåˆ©ç”¨RNAæµ‹åºæŠ€æœ¯å‘ç°æ–°çš„å…ç–«ç”Ÿç‰©æ ‡å¿—ç‰©ç”¨äºç»“æ ¸ç—…è¯Šæ–­ï¼Œå¹¶åˆ†æèšŠå­ç—…æ¯’ç»„ä»¥ç›‘æµ‹ç–¾ç—…ä¼ æ’­ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- <strong>RNAæµ‹åºï¼ˆRNA-seqï¼‰</strong>ï¼šåœ¨è¯Šæ–­ã€ç—…æ¯’ç»„å­¦ç ”ç©¶å’Œå•ç»†èƒè½¬å½•ç»„å­¦å·¥ä½œæµç¨‹è‡ªåŠ¨åŒ–ä¸­å‘æŒ¥å…³é”®ä½œç”¨ã€‚<br />
- <strong>æ–°å‹é€’é€ç³»ç»Ÿ</strong>ï¼šå¾®å‹è¯ç‰©é‡Šæ”¾æ¤å…¥ç‰©å’Œæ˜“äºç©¿é€å¤§è„‘çš„çº³ç±³æŠ—ä½“ä¸ºç–¾ç—…æ²»ç–—å¸¦æ¥æ–°æ–¹æ³•ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (51æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>å®«é¢ˆç™Œæˆçº¤ç»´ç»†èƒçš„è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒè§£æï¼šåŸºäºå•ç»†èƒä¸ç©ºé—´è½¬å½•ç»„å­¦çš„æ·±å…¥æ¢ç´¢</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šä½œå›¾ä¸«<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«ã€å…ç–«å¾®ç¯å¢ƒã€å•ç»†èƒã€ç©ºé—´è½¬å½•ç»„ã€ç©ºé—´ç»„å­¦ã€è½¬å½•ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šæœ€è¿‘æœ‰å°ä¼™ä¼´åæ˜ æ”¶ä¸åˆ°æ¨é€ï¼Œå› ä¸ºå…¬ä¼—å·æ”¹äº†æ¨é€ç®—æ³•ï¼Œç°åœ¨éœ€è¦åŠ æ˜Ÿæ ‡ï¼Œå¤šç‚¹èµã€ç‚¹åœ¨çœ‹ï¼Œæ‰èƒ½å‡†æ—¶æ”¶åˆ°æ¨é€å“¦ã€‚<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg2NTE1MzU4NQ==&amp;mid=2247523399&amp;idx=1&amp;sn=3c7a3a899361e9207867c634f747ac15" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>åˆä¸€ç¯‡æ°¨åŸºé…¸ä»£è°¢ç”Ÿä¿¡ã€‚æœ¬æ–‡èšç„¦ç»„æ°¨é…¸ä»£è°¢å¯¹è‚¿ç˜¤å…ç–«çš„æŠ‘åˆ¶ä½œç”¨ï¼Œç»“åˆå®éªŒéªŒè¯ã€‚æ˜¯ä¸€ç¯‡å¹²æ¹¿ç»“åˆçš„å¥½æ–‡ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«ã€ä»£è°¢ã€ä»£è°¢ç»„ã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503943&amp;idx=4&amp;sn=82b312ddfdc23f2b9a900906c4305558" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>åˆšåˆšå‘è¡¨7.5åˆ†ç”Ÿä¿¡ï¼Œèšç„¦æ–°çƒ­ç‚¹æ£•æ¦ˆé…°åŒ–ï¼Œå•ç»†èƒ+æ— ç›‘ç£èšç±»+ç™¾ç§æœºå™¨å­¦ä¹ +ç®€å•éªŒè¯ã€‚éè‚¿ç˜¤ç”Ÿä¿¡æ¨¡æ¿ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šä¸œæ™“ç”Ÿç‰©<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å•ç»†èƒã€ç”Ÿä¿¡ã€èšç±»<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTU2MzM2NA==&amp;mid=2247493004&amp;idx=1&amp;sn=c755b1efd4051bb073d5a927fd8df30c" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>å•ç»†èƒè½¬å½•ç»„ç»˜åˆ¶MASHå‘è‚ç™Œè½¬åŒ–å…ç–«å¾®ç¯å¢ƒå…¨æ™¯å›¾è°±</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå•ç»†èƒå¤©åœ°<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å…ç–«å¾®ç¯å¢ƒã€å•ç»†èƒã€è½¬å½•ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šæ–‡ç« ç®€ä»‹åŠèƒŒæ™¯ä»‹ç» å•ç»†èƒæµ‹åºæ•°æ®ç®€ä»‹ ä¸»è¦åˆ†æç»“æœæ¦‚è¿°<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&amp;mid=2247533603&amp;idx=1&amp;sn=a39eea4ed83b152b5b7725efa3b06d85" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>CancerSCEM - ç™Œç—‡å•ç»†èƒè¡¨è¾¾å›¾è°±ã€å›½å®¶ç”Ÿç‰©ä¿¡æ¯ä¸­å¿ƒã€‘</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡èœé¸Ÿå›¢<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€å•ç»†èƒã€ç”Ÿç‰©ä¿¡æ¯ã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç™Œç—‡å•ç»†èƒè¡¨è¾¾å›¾è°±ï¼ˆCancer Single-cell Expression Mapï¼‰ï¼ˆhttps://ng<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzUzMTEwODk0Ng==&amp;mid=2247538000&amp;idx=1&amp;sn=4908ae14f38d2065eaf2db6dd57dbeb3" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>IF 25+ |å± å‘¦å‘¦å›¢é˜Ÿåˆ©ç”¨å•ç»†èƒæµ‹åºå‘ç°é’è’¿ç´ å…ç–«è°ƒèŠ‚æ–°æœºåˆ¶ï¼Œç”Ÿä¿¡å¼€æºä»£ç å­¦ä¹ </strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡é’±åŒå­¦<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€æµ‹åºã€å•ç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šå¥½çš„å•ç»†èƒç”Ÿä¿¡ä»£ç å­¦ä¹ <br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495519&amp;idx=1&amp;sn=72415374acd7a019b7ca977842dfa56e" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>Nat Biomed Eng | è…¾è®¯å¼€å‘ç”¨äºå°†å•ç»†èƒè½¬å½•ç»„ç¿»è¯‘æˆè›‹ç™½è´¨ç»„çš„é¢„è®­ç»ƒå¤§å‹ç”Ÿæˆæ¨¡å‹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šäººä½“è›‹ç™½è´¨ç»„å¯¼èˆªè®¡åˆ’<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå•ç»†èƒã€è½¬å½•ç»„ã€è›‹ç™½è´¨ç»„ã€ç»„è›‹ç™½<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247506980&amp;idx=3&amp;sn=47594ae9ca6523cd74a6d5fd11d40429" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>èšç„¦æ°¨åŸºé…¸ä»£è°¢çƒ­ç‚¹ï¼Œç»“åˆç™¾ç§æœºå™¨å­¦ä¹ +å•ç»†èƒ+Scissor +å…ç–«æ²»ç–—+è¡¨è¾¾éªŒè¯ï¼Œä¸€ç¯‡2åŒºæ–‡ç« å°±åˆ°æ‰‹äº†ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€ä»£è°¢ã€å•ç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503943&amp;idx=5&amp;sn=a87da62c71c09393ebcb3bdd2fb99591" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>æ°¨åŸºé…¸ä»£è°¢çƒ­åº¦ä¸å‡ï¼šæœ€æ–°ç”Ÿä¿¡å‘æ–‡ï¼Œé¶å‘è°·æ°¨é…°èƒºä»£è°¢å¢åŠ å…ç–«æ²»ç–—ç–—æ•ˆï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€ä»£è°¢ã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503943&amp;idx=1&amp;sn=be30928f95d3cdab93bc3f1aaabd0a20" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> â­ <strong>è‚¿ç˜¤ç¼©å°è¶…å…«æˆï¼æ–°ç ”ç©¶å‘ç°æœ‰æœ›æ”»å…‹ç™Œç—‡è€è¯çš„ERKæŠ‘åˆ¶å‰‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå­¦æœ¯ç»çº¬<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€ç™Œç—‡ã€è€è¯<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šæœ‰æœ›å…‹æœè·å¾—æ€§è€è¯<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568668&amp;idx=2&amp;sn=106543c71c87f90806c9289b22d18171" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 41 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-å…¬ä¼—å·">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (23æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE291339 CDK4/6 æŠ‘åˆ¶å‰‚ Palbociclib å…‹æœäº† Venetoclax è€è¯æœºåˆ¶ï¼Œå¹¶åœ¨æ€¥æ€§é«“ç³»ç™½è¡€ç—…ä¸­ä¼˜äºå•è¯æ²»ç–— [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemiaã€resistanceã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Melissa L Stewart ; Jessica Gibbs ; Andy Kaempf ; Jeffrey W TynerSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensVenetoclax (ven) combined with the hypomethylating agent azacytidine (aza) is a widely used therapy for Acute Myeloid Leukemia (AML), however, most patients develop resistance. Using RNASeq, we identified loss of Ikaros (IKZF1) as a potential resistance mechanism to ven+palbo. Examination of cells with IKZF1-loss revealed upregulation of the receptor, AXL, with concordant AXL inhibitor sensitivity in AML tumors harboring IKZF1 mutations. This work suggests that the combination of ven+palbo is a potential novel therapy for AML for potential subpopulations that may benefit the most from this treatment, as well as targeting translation as a means to overcome ven resistance.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291339" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>GSE291338 CDK4/6 æŠ‘åˆ¶å‰‚ Palbociclib å…‹æœäº† Venetoclax è€è¯æœºåˆ¶ï¼Œå¹¶åœ¨æ€¥æ€§é«“ç³»ç™½è¡€ç—…ä¸­ä¼˜äºå•è¯æ²»ç–— [CRISPR ç­›é€‰]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemiaã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Melissa L Stewart ; Jessica Gibbs ; Daniel Bottomly ; Shannon K McWeeney ; Jeffrey W TynerSeries Type : OtherOrganism : Homo sapiensVenetoclax (ven) combined with the hypomethylating agent azacytidine (aza) is a widely used therapy for Acute Myeloid Leukemia (AML), however, most patients develop resistance. A genome-wide CRISPR screen showed that loss of genes involved in translation conferred sensitivity to ven but not ven+palbo. Accordingly, we show that increased translation occurs after AML cells are challenged with ven, and ven+palbo blocks this increase. We also found that loss of BAX, which leads to ven resistance, was overcome by combination with CDK4/6 inhibitors. Conversely, loss of RB1, a known mechanism of resistance to CDK4/6 inhibitors, was mitigated by ven+palbo. This work suggests that the combination of ven+palbo is a potential novel therapy for AML for potential subpopulations that may benefit the most from this treatment, as well as targeting translation as a means to overcome ven resistance.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291338" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>GSE271857 Phase separation mediates AKAP95 regulating oncogenic MLL-fusion driven transcription and its application in leukemia therapy (RNA-Seq)</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemiaã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Bi Shi ; Yongkun Luan ; Hao Jiang ; Wei LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusOncogenic transcription represents a crucial event in MLL rearranged (MLLr) leukemia, yet the precise role of transcription co-activators in MLL-fusion protein-associated transcription and their contribution to leukemogenesis remain incompletely understood. Here, we demonstrate that AKAP95 is notably up-regulated in both MLLr patients and in MLL-AF9-transformed mouse bone marrow. AKAP95 proves essential for initiating mouse MLL-AF9 leukemia, exhibiting widespread DNA binding across the genome, particularly at gene promoters. Interaction with the translocated MLL1 fragment primarily occurs through phase separation mechanisms. AKAP95's RNA-binding properties, coupled with its phase separation behavior, govern its binding to pre-mRNA and concurrent transcriptional regulation. Importantly, we engineered a peptide to disrupt its phase separation, effectively attenuating AKAP95-mediated transcriptional co-activation and inhibiting the growth of MLLr cell lines. These findings illustrate a vivid example of an RNA-binding protein orchestrating transcription and tumorigenesis via phase separation, underscoring the potential for targeting oncogenic condensation mechanisms therapeutically.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271857" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>GSE271854 Phase separation mediates AKAP95 regulating oncogenic MLL-fusion driven transcription and its application in leukemia therapy (ChIP-Seq)</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemiaã€ChIP-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Bi Shi ; Yongkun Luan ; Hao Jiang ; Wei LiSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensOncogenic transcription represents a crucial event in MLL rearranged (MLLr) leukemia, yet the precise role of transcription co-activators in MLL-fusion protein-associated transcription and their contribution to leukemogenesis remain incompletely understood. Here, we demonstrate that AKAP95 is notably up-regulated in both MLLr patients and in MLL-AF9-transformed mouse bone marrow. AKAP95 proves essential for initiating mouse MLL-AF9 leukemia, exhibiting widespread DNA binding across the genome, particularly at gene promoters. Interaction with the translocated MLL1 fragment primarily occurs through phase separation mechanisms. AKAP95's RNA-binding properties, coupled with its phase separation behavior, govern its binding to pre-mRNA and concurrent transcriptional regulation. Importantly, we engineered a peptide to disrupt its phase separation, effectively attenuating AKAP95-mediated transcriptional co-activation and inhibiting the growth of MLLr cell lines. These findings illustrate a vivid example of an RNA-binding protein orchestrating transcription and tumorigenesis via phase separation, underscoring the potential for targeting oncogenic condensation mechanisms therapeutically.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271854" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>GSE297256 å•ç»†èƒæ˜ å°„æ­ç¤ºéª¨è†œç¥–ç»†èƒå’Œå…ç–«å¾®ç¯å¢ƒçš„å¹´é¾„ç›¸å…³æ”¹å˜ï¼Œè¿™äº›æ”¹å˜ä¼šæŸå®³éª¨å†ç”Ÿ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Lei Zhao ; Chao WuSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAging profoundly impacts bone homeostasis and regeneration, yet the cellular and molecular mechanisms underlying periosteal aging remain poorly understood. Using single-cell RNA sequencing, we profiled the periosteum of 3-, 9-, and 18-month-old mice, revealing age-related shifts in progenitor, neutrophil, and macrophage subpopulations. Aging reduced mesenchymal cell populations and impaired osteogenic potential, disrupting periosteal homeostasis. Periosteal progenitor subsets exhibited distinct aging trajectories: Dptâº fibrous-layer cells undergoing early senescence, while Postnâº progenitors showed osteogenic decline. Aging also shifted immune profiles, increasing inflammatory Cd38hi macrophages and dysfunctional Nlrp3hi neutrophils, further disrupting bone homeostasis. Notably, aged progenitor cells upregulated CSF1 and CXCL signaling, driving macrophage and neutrophil infiltration, exacerbating bone loss. Our findings provide a comprehensive periosteal aging atlas, highlighting disrupted progenitor-immune crosstalk as a key driver of bone homeostasis imbalance and impaired regeneration, offering potential therapeutic targets for age-related bone disorders.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297256" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE280833 ç»„è›‹ç™½H4å¯¹ç»„è›‹ç™½åŸºå› è½¬å½•çš„ç»†èƒå‘¨æœŸä¾èµ–æ€§æŠ‘åˆ¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šhistone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Kami Ahmad ; Matt Wooten ; Brittany N Takushi ; Velinda Vidaurre ; Xin Chen ; Steven HenikoffSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Drosophila melanogaster ; Homo sapiensIn all eukaryotes DNA replication is coupled to histone synthesis to coordinate chromatin packaging of the genome. Canonical histone genes coalesce in the nucleus into the Histone Locus Body (HLB), where gene transcription and 3â€™ mRNA processing occurs. Both histone gene transcription and mRNA stability are reduced when DNA replication is inhibited, implying that the Histone Locus Body senses the rate of DNA synthesis. In Drosophila melanogaster, the S-phase-induced histone genes are repeated in an ~100 copy repeat unit array, whereas in humans, these histone genes are scattered. In both organisms these genes coalesce into Histone Locus Bodies.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280833" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE309408 æ¯”è¾ƒçœ¼è½¬å½•ç»„å›¾è°±</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štranscriptome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Christian Damsgaard ; Lin LinSeries Type : Other ; Expression profiling by high throughput sequencingOrganism : Anolis carolinensis ; Columba livia ; Gallus gallus ; Taeniopygia guttataThe Comparative Eye Transcriptome Atlas provides transcriptomic resources to study retinal evolution and physiology across non-mammalian vertebrates. We profiled retinas from four species using two complementary high-throughput approaches. Eight 10x Genomics Visium spatial transcriptomics datasets were generated from Anolis carolinensis (n = 2), Taeniopygia guttata (n = 4), Columba livia (n = 1), and Gallus gallus (n = 1), capturing spatially resolved gene expression with matched histology images. In parallel, six 10x Genomics Chromium Single Cell 3â€² RNA-seq datasets were obtained from zebra finch (T. guttata) retinas to resolve cell-typeâ€“specific transcriptomes. Raw sequencing data (FASTQ) and processed outputs from SpaceRanger (Visium) and CellRanger (Chromium) are provided. Downstream integrated and annotated datasets can be explored interactively at https://linlab.au.dk/Damsgaard_lab/CETA/ and full Seurat objects are available on request.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309408" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE308249 å‰ªæ¥å› å­ PTBP1 ä¸ RUNX1 ç›¸äº’ä½œç”¨ï¼Œæ˜¯ç™½è¡€ç—…ç»†èƒå­˜æ´»æ‰€å¿…éœ€çš„ [é•¿ç¯‡é˜…è¯»]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemia<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Arjun Dhir ; Alexander Ethell ; Riley Watkins ; Calvin Lam ; Kevin Tur-Rodriguez ; Jimmie Persinger ; Kasidy K Dobish ; Sipra Panda ; Shannon M Buckley ; Samantha A Swenson ; Sandipan Brahma ; Jordan Rowley ; Katherine HydeSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensRunt-related Transcription Factor 1 (RUNX1) is essential for definitive hematopoiesis and is among the most frequently mutated genes in leukemia. Previous work from our lab demonstrated that Histone Deacetylase 1 (HDAC1), a known RUNX1 partner, is unexpectedly required for active transcription suggesting a non-histone role for HDAC1 regulating components of the RUNX1 complex. Here, we use proteomics, genomics, and long-read transcriptomics to identify novel RUNX1 interacting partners and decipher their role in gene regulation and RNA splicing in leukemia cells. We demonstrate that Polypyrimidine Tract Binding Protein 1 (PTBP1) interacts with RUNX1 in an HDAC1-dependent manner. Chromatin profiling revealed extensive genome-wide overlap in sites occupied by RUNX1 and PTBP1, with significant enrichment at promoters of actively transcribed genes. Loss of PTBP1 in AML cells led to widespread alterations in RNA splicing and decreased expression of genes whose promoters are bound by both factors, including metabolic genes. In agreement with these findings, we found that loss of PTBP1 reduced glycolysis and glucose uptake and ultimately caused cell death. Based on our data, we propose that the interaction between RUNX1 and PTBP1 facilitates expression of metabolic proteins essential for leukemia cell growth and survival.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308249" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE308248 å‰ªæ¥å› å­ PTBP1 ä¸ RUNX1 ç›¸äº’ä½œç”¨ï¼Œæ˜¯ç™½è¡€ç—…ç»†èƒå­˜æ´»æ‰€å¿…éœ€çš„ [CUT&amp;Tag]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemia<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Arjun Dhir ; Alexander Ethell ; Riley Watkins ; Calvin Lam ; Kevin Tur-Rodriguez ; Jimmie Persinger ; Kasidy K Dobish ; Sipra Panda ; Shannon M Buckley ; Samantha A Swenson ; Sandipan Brahma ; Jordan Rowley ; Katherine HydeSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensRunt-related Transcription Factor 1 (RUNX1) is essential for definitive hematopoiesis and is among the most frequently mutated genes in leukemia. Previous work from our lab demonstrated that Histone Deacetylase 1 (HDAC1), a known RUNX1 partner, is unexpectedly required for active transcription suggesting a non-histone role for HDAC1 regulating components of the RUNX1 complex. Here, we use proteomics, genomics, and long-read transcriptomics to identify novel RUNX1 interacting partners and decipher their role in gene regulation and RNA splicing in leukemia cells. We demonstrate that Polypyrimidine Tract Binding Protein 1 (PTBP1) interacts with RUNX1 in an HDAC1-dependent manner. Chromatin profiling revealed extensive genome-wide overlap in sites occupied by RUNX1 and PTBP1, with significant enrichment at promoters of actively transcribed genes. Loss of PTBP1 in AML cells led to widespread alterations in RNA splicing and decreased expression of genes whose promoters are bound by both factors, including metabolic genes. In agreement with these findings, we found that loss of PTBP1 reduced glycolysis and glucose uptake and ultimately caused cell death. Based on our data, we propose that the interaction between RUNX1 and PTBP1 facilitates expression of metabolic proteins essential for leukemia cell growth and survival.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308248" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE299947 Plagl1 å’Œ Lrrc58 é€šè¿‡è§¦å‘ miR-322 å’Œ miR-503 çš„é¶å‘ microRNA é™è§£æ¥æ§åˆ¶å“ºä¹³åŠ¨ç‰©çš„ä½“å‹ [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Collette A LaVigne ; Jaeil Han ; He Zhang ; Sihoon Cho ; Minseon Kim ; Komal Sethia ; Bret M Evers ; Asha Acharya ; Tsung-Cheng Chang ; Joshua T MendellSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusPrecise control of microRNA (miRNA) expression is critical for normal development. An important mechanism of miRNA regulation is target-directed microRNA degradation (TDMD), a pathway in which the binding of miRNAs to specialized trigger RNAs induces ubiquitylation and decay of associated Argonaute (AGO) proteins by the ZSWIM8 ubiquitin ligase. ZSWIM8-deficient mice exhibit reduced body size, cardiopulmonary and neurodevelopmental defects, and perinatal lethality. Despite widespread dysregulation of miRNAs in these animals, the vast majority of presumptive trigger RNAs that induce decay of ZSWIM8-regulated miRNAs remain undefined. Here, using AGO crosslinking and sequencing of hybrids (AGO-CLASH), a high-throughput method for identifying miRNA binding sites, we report the identification of Plagl1 as a trigger for TDMD of miR-322-5p, and Lrrc58 and Malat1 as TDMD triggers for miR-503-5p in mouse embryonic fibroblasts (MEFs). In mice, deletion of the miR-322-5p and miR-503-5p trigger sites in the Plagl1 and Lrrc58 3' UTRs, respectively, abrogated TDMD of these miRNAs and resulted in miR-322/503-dependent embryonic growth restriction, recapitulating a key feature of the Zswim8â€”/â€” phenotype. Thus, these results demonstrate that the transcripts encoding Plagl1 and Lrrc58 regulate mammalian body size by inducing degradation of miR-322-5p and miR-503-5p and provide a valuable resource for identification of additional TDMD triggers.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299947" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 13 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (4æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>è¯„ä¼°ä¸¤å‰‚å¶é…¸å—ä½“ Î± ç–«è‹—åœ¨ä¸‰é˜´æ€§ä¹³è…ºç™Œæ‚£è€…ä¸­çš„å®‰å…¨æ€§å’Œå…ç–«åŸæ€§çš„ II æœŸè¯•éªŒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€ç–«è‹—<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç›®çš„ï¼šCD4 T ç»†èƒå…ç–«ä¸æé«˜ä¹³è…ºç™Œæ‚£è€…çš„ç”Ÿå­˜ç‡æœ‰å…³ã€‚æˆ‘ä»¬ä¹‹å‰æŠ¥é“äº†ä¸€é¡¹è¯„ä¼°å¶é…¸å—ä½“Î±ï¼ˆFRÎ±ï¼‰ç–«è‹—ä¸ç¯ç£·é…°èƒºï¼ˆCPï¼‰ä¸€èµ·ç»™è¯çš„ I æœŸè¯•éªŒï¼Œè¯¥è¯•éªŒæ˜¾ç¤ºå‡ºå‡ºè‰²çš„å®‰å…¨æ€§å’Œå…ç–«åŸæ€§ã€‚ä¸ºäº†ç®€åŒ–ç–«è‹—ç­–ç•¥ä»¥ä½¿å…¶æ˜“äºä½¿ç”¨ï¼Œæˆ‘ä»¬åœ¨æ­¤æŠ¥å‘Šäº†ä¸€é¡¹éšæœº II æœŸè¯•éªŒçš„ç»“æœï¼Œè¯¥è¯•éªŒè¯„ä¼°äº†è¾ƒä½çš„ç–«è‹—å‰‚é‡å’ŒåŸå§‹å‰‚é‡ï¼Œåœ¨æœ‰æˆ–æ²¡æœ‰ç¯ç£·é…°èƒºé¢„å¤„ç†çš„æƒ…å†µä¸‹ç»™è¯ã€‚æ‚£è€…å’Œæ–¹æ³•ï¼šå®Œæˆæ‰€æœ‰å…¨èº«å’Œå±€éƒ¨æ²»ç–—çš„ä¸‰é˜´æ€§ä¹³è…ºç™Œ ï¼ˆTNBCï¼‰ æ‚£è€…è¢«åˆ†é…æ¥å—ä½å‰‚é‡ ï¼ˆ825 mgï¼‰ æˆ–é«˜å‰‚é‡ ï¼ˆ2.5 mgï¼‰ ç–«è‹—è‚½åŠ  GM-CSF åœ¨å…­ä¸ª 4 å‘¨å‘¨æœŸå†…ï¼Œæ¥ç§ç–«è‹—å‰æœ‰æˆ–æ²¡æœ‰ CPã€‚åœ¨ç–«è‹—æ¥ç§å‰åç›‘æµ‹å®‰å…¨æ€§å¹¶è¯„ä¼°å…ç–«åŸæ€§ã€‚ç»“æœï¼šå…± 80 ä¾‹æ‚£è€…æ¥ç§ç–«è‹—ï¼Œ58 ä¾‹æ‚£è€…å…ç–«åŸæ€§å¯è¯„ä¼°ã€‚ç–«è‹—æ¥ç§è€å—æ€§è‰¯å¥½ï¼Œ83% çš„æ‚£è€…äº§ç”Ÿäº†å…ç–«åŠ›ã€‚FRÎ±ç‰¹å¼‚æ€§ T ç»†èƒæ°´å¹³é«˜ã€æŒä¹…ï¼Œä¸æŠ—ç ´ä¼¤é£ç±»æ¯’ç´ çš„ T ç»†èƒæ°´å¹³ç›¸å½“ã€‚ä¸¤ç§å‰‚é‡ä¹‹é—´çš„å…ç–«åŠ›æ²¡æœ‰å·®å¼‚ã€‚CP é¢„å¤„ç†ä¹Ÿä¸å½±å“å…ç–«ååº”ã€‚8<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1988351415817449472/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>USP20 é©±åŠ¨çš„èƒ†å›ºé†‡ä»£è°¢å°†ç‚ç—‡ä¿¡å·ä¼ å¯¼ä¸èƒ°è…ºç™Œçš„æ¶æ€§è‚¿ç˜¤å’ŒåŸºè´¨å…±åŒè¿›åŒ–è”ç³»èµ·æ¥</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€ä»£è°¢<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç‚ç—‡ä¿¡å·ä¼ å¯¼ã€ä»£è°¢é‡ç¼–ç¨‹å’ŒåŸºè´¨å¤æ‚æ€§å·²æˆä¸ºèƒ°è…ºå¯¼ç®¡è…ºç™Œ ï¼ˆPDACï¼‰ çš„æ ¸å¿ƒæ ‡å¿—ã€‚è¿™äº›ç¨‹åºä¹‹é—´çš„ä¸²æ‰°å¯èƒ½ä»£è¡¨åŒæ—¶æ‰°ä¹±å¤šä¸ªè‚¿ç˜¤ä¿ƒè¿›è¿‡ç¨‹çš„æ½œåœ¨é¶ç‚¹ã€‚é€šè¿‡æ•´åˆæ¥è‡ªä¸´åºŠé˜Ÿåˆ—ã€æ‚£è€…æ¥æºçš„ç±»å™¨å®˜å’Œæœ¬åœŸæ¨¡å‹çš„å¤šç»„å­¦æ•°æ®ï¼Œæˆ‘ä»¬å‘ç° PDAC ä¸­çš„è‚¿ç˜¤å†…æºæ€§ç‚ç—‡çº§è”ååº”æ˜¯ç”²ç¾ŸæˆŠé…¸é€”å¾„åŠ«æŒçš„ä¸»è¦è°ƒèŠ‚å› å­ï¼Œè¿™æ¨åŠ¨äº†æ¶æ€§è¿›å±•å’ŒåŸºè´¨å…±åŒè¿›åŒ–ã€‚TNFSF13B+ è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒæ¿€æ´»è‚¿ç˜¤ä¸Šçš®ç»†èƒä¸­çš„ STAT3 ä¿¡å·ä¼ å¯¼ï¼Œå¯¼è‡´ USP20 çš„è½¬å½•ä¸Šè°ƒã€‚è¿™ç§å»æ³›ç´ é…¶ç¨³å®šäº† HMGCRï¼Œä»¥å¢å¼ºç”²ç¾ŸæˆŠé…¸é€šé‡ï¼Œå¯¼è‡´èƒ†å›ºé†‡å’Œé¦™å¶åŸºé¦™å¶é…°ç„¦ç£·é…¸ç›çš„äº§ç”Ÿè¿‡é‡ã€‚USP20 ä»‹å¯¼çš„ä»£è°¢æ”¹å˜è¯±å¯¼çš„ YAP/TAZ ä¿¡å·ä¼ å¯¼åˆºæ¿€ä¿ƒè¿›è‚¿ç˜¤ç»†èƒå¢æ®–å¹¶è§¦å‘ç™Œç—‡ç›¸å…³æˆçº¤ç»´ç»†èƒ ï¼ˆCAFï¼‰ çš„æ¿€æ´»ã€‚ä½¿ç”¨é€‰æ‹©æ€§æŠ‘åˆ¶å‰‚å¯¹ USP20 è¿›è¡ŒåŸºå› æ¶ˆèæˆ–è¯ç†å­¦æŠ‘åˆ¶å¯é€†è½¬è‚¿ç˜¤ä»£è°¢å¤±è°ƒï¼Œä»è€ŒæŠ‘åˆ¶è‚¿ç˜¤ç”Ÿé•¿å’ŒåŸºè´¨ç»“ç¼”å¢ç”Ÿã€‚æ­¤å¤–ï¼ŒUSP20 æŠ‘åˆ¶ä¸æŠ— PD-1/æŠ— CTLA-4<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1986639189233016832/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒäº§ç”Ÿ PGE2 ä»¥ä¿ƒè¿› CD8+ T ç»†èƒè€—ç«­å¹¶é©±åŠ¨å¾®å«æ˜Ÿç¨³å®šç»“ç›´è‚ ç™Œå¯¹ PD-L1 é˜»æ–­çš„è€è¯æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€è€è¯<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: å…ç–«æ£€æŸ¥ç‚¹é˜»æ–­æ²»ç–—å¯¹å¾®å«æ˜Ÿä¸ç¨³å®š ï¼ˆMSIï¼‰ ç»“ç›´è‚ ç™Œ ï¼ˆCRCï¼‰ éå¸¸æœ‰æ•ˆã€‚ç„¶è€Œï¼Œå¾®å«æ˜Ÿç¨³å®š ï¼ˆMSSï¼‰ è‚¿ç˜¤å¯¹å…ç–«æ²»ç–—å…·æœ‰å†…åœ¨çš„è€è¯æ€§ã€‚åœ¨è¿™é‡Œï¼Œæˆ‘ä»¬è¯•å›¾é€šè¿‡è¡¨å¾ MSS å’Œ MSI è‚¿ç˜¤æ¨¡å‹çš„å…ç–«è°±æ¥æ›´å¥½åœ°äº†è§£ CRC ä¸­æŠ— PD-L1 æ²»ç–—è€è¯çš„æœºåˆ¶ã€‚è™½ç„¶ä¸¤ç§è‚¿ç˜¤ç±»å‹éƒ½è¡¨ç°å‡ºç˜¤å†… CD8+ T ç»†èƒå’Œ PD-L1 è¡¨è¾¾ï¼Œä½†è€—å°½çš„ CD8+ T ç»†èƒè¡¨å‹ä¸åŒã€‚åœ¨ MSS è‚¿ç˜¤ä¸­ï¼Œè€—å°½çš„ CD8 + T ç»†èƒå…±è¡¨è¾¾ PD-1 å’Œ TIGITï¼Œå¹¶è¡¨ç°å‡ºç»ˆæœ«è€—å°½ç‰¹å¾ï¼Œç»†èƒå› å­åˆ†æ³Œä½ï¼Œç»†èƒæ¯’æ€§åŠŸèƒ½æœ‰é™ã€‚ç›¸æ¯”ä¹‹ä¸‹ï¼ŒMSI è‚¿ç˜¤ä¸­çš„ PD-1+ CD8+ T ç»†èƒä¸è¡¨è¾¾ TIGITï¼Œè¡¨ç°å‡ºæ›´é«˜çš„ç»†èƒå› å­å’Œç»†èƒæ¯’æ€§æ´»æ€§ã€‚æœ‰è¶£çš„æ˜¯ï¼Œå…ç–«æŠ‘åˆ¶æ€§ M2 æ ·è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒï¼ˆTAMï¼‰åœ¨ MSI è‚¿ç˜¤ä¸­ç§¯ç´¯ï¼Œå¹¶ä¸ PD-1+ TIGIT+ CD8+ T ç»†èƒé¢‘ç‡å‘ˆæ­£ç›¸å…³ã€‚M2 æ · TAM è€—ç«­é™ä½äº† TIGIT<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1986639195407032320/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>ä¸€ç§ç”± hsa_circ_0065394 ç¼–ç çš„æ–°å‹è›‹ç™½ cPFKFB4 å¯å¢å¼º PKM2 ä»‹å¯¼çš„è‘¡è„ç³–ä»£è°¢é‡ç¼–ç¨‹ï¼Œä¿ƒè¿›ç¼ºæ°§ä¸‹èƒ°è…ºç™Œè¿›å±•</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šä»£è°¢<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç¼ºæ°§æ˜¯å®ä½“ç˜¤çš„æ ‡å¿—ï¼Œå¯å¼•èµ·ç™Œç—‡çš„è‘¡è„ç³–ä»£è°¢é‡ç¼–ç¨‹ã€‚ç”±ç¯çŠ¶ RNA ï¼ˆcircRNAï¼‰ ç¼–ç çš„è‚½å’Œè›‹ç™½è´¨è¢«ç¡®å®šä¸ºè‚¿ç˜¤æ¶æ€§è¿›å±•çš„å…³é”®ä»‹è´¨ã€‚å°½ç®¡å¦‚æ­¤ï¼Œèƒ°è…ºç™Œ ï¼ˆPCï¼‰ ä¸­ç¼ºæ°§ç›¸å…³ circRNA ç¼–ç çš„è›‹ç™½è´¨ä»ç„¶æœªè¡¨å¾ä¸”çŸ¥ä¹‹ç”šå°‘ã€‚ä½¿ç”¨ç¼ºæ°§åŸ¹å…»ç³»ç»Ÿç­›é€‰ PC ä¸­ç¼ºæ°§ååº”æ€§ circRNAï¼ˆhsa_circ_0065394ï¼‰ã€‚é‡‡ç”¨ç”Ÿç‰©ä¿¡æ¯å­¦å’Œ RNA å…ç–«æ²‰æ·€ç ”ç©¶äº† hsa_circ_0065394 çš„ç¯åŒ–æœºåˆ¶ã€‚åˆ©ç”¨ qRT-PCR å’ŒåŸä½æ‚äº¤å¯¹ hsa_circ_0065394 åœ¨ PC ä¸­çš„è¡¨è¾¾è°±å’Œæ½œåœ¨ä¸´åºŠæ„ä¹‰è¿›è¡Œè¯„ä¼°ã€‚åŒè§å…‰ç´ é…¶æŠ¥å‘ŠåŸºå› æ£€æµ‹ã€è´¨è°±å’Œè›‹ç™½è´¨å°è¿¹é‰´å®šå‡ºç”± hsa_circ_0065394 ç¼–ç çš„è›‹ç™½ cPFKFB4ã€‚é€šè¿‡ä½“å†…å’Œä½“å¤–åŠŸèƒ½è·å¾—å’Œä¸§å¤±å®éªŒéªŒè¯äº† cPFKFB4 çš„ç”Ÿç‰©å­¦åŠŸèƒ½ã€‚ä»æœºåˆ¶è§’åº¦å‡ºå‘ï¼Œé€šè¿‡è´¨è°±ã€å…ç–«å…±æ²‰æ·€ã€å…ç–«è§å…‰ã€PKM å‰ªæ¥ã€RNA å…ç–«æ²‰æ·€ã€è›‹ç™½è´¨å°è¿¹å’ŒæŠ¢æ•‘å®éªŒç­‰æ–¹æ³•ï¼Œæ¢è®¨äº†<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1988451054084272128/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (12æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>RNAæµ‹åºæ­ç¤ºäº†å¯ç”¨äºæ”¹è¿›è‚ºå¤–ç»“æ ¸ç—…è¯Šæ–­çš„å…ç–«ç”Ÿç‰©æ ‡å¿—ç‰©</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€sequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šRNA sequencing identifies immune biomarkers for extrapulmonary tuberculosis, revealing new molecular signatures in blood that may improve diagnosis and enable personalized treatment...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/rna-sequencing-reveals-immune-biomarkers-for-improved-diagnosis-of-extrapulmonary-tuberculosis/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>New bacterial therapy destroys cancer without the immune system</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immune<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA Japanese-led research team has developed AUN, a groundbreaking immune-independent bacterial cancer therapy that uses two harmonized bacteria to destroy tumors even in patients with weakened immune systems. By leveraging the natural synergy between Proteus mirabilis and Rhodopseudomonas palustris, AUN selectively targets cancer cells, reshapes itself within tumors, and avoids harmful side effects like cytokine release syndrome.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251109013250.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>SPT Labtech å’Œ Alithea Genomics åˆä½œï¼Œå®ç°è¶…çµæ•å•ç»†èƒè½¬å½•ç»„å­¦å·¥ä½œæµç¨‹çš„è‡ªåŠ¨åŒ–</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsingle-cellã€genomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, and Alithea Genomics, a pioneer in the field of large-scale RNA sequencing and transcriptomics, today announced a collaboration to provide an automated solution for single-cell transcriptomics. The collaboration integrates Alithea Genomicsâ€™ ultra-sensitive single-cell RNA-seq technology, MERCURIUSâ„¢ FLASH-seq, ...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/spt-labtech-and-alithea-genomics-collaborate-to-automate-ultra-sensitive-single-cell-transcriptomic-workflows/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>åˆ©ç”¨å°RNAæµ‹åºæŠ€æœ¯å¯¹è·—åº“èšŠè¿›è¡Œç—…æ¯’ç»„åˆ†æ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šRNA sequencing reveals diverse insect-specific viruses in Culex tarsalis mosquitoes, improving understanding of viral interactions and aiding mosquito-borne disease surveillance...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/virome-profiling-of-culex-tarsalis-through-small-rna-seq/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>Tiny implant wipes out bladder cancer in 82% of patients</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šTAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, consistent release of chemotherapy proved far more effective than traditional short-term treatments. The therapy may replace bladder removal surgery for many and has earned FDA Priority Review due to its impressive results.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251111010000.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>Clearing brain plaques isnâ€™t enough to heal Alzheimerâ€™s</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šJapanese researchers found that lecanemab, an amyloid-clearing drug for Alzheimerâ€™s, does not improve the brainâ€™s waste clearance system in the short term. This implies that nerve damage and impaired clearance occur early and are difficult to reverse. Their findings underscore that tackling amyloid alone may not be enough to restore brain function, urging a broader approach to treatment.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251111005944.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>Hidden weakness makes prostate cancer self-destruct</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy. When blocked, these enzymes cause the androgen receptor to collapse, killing cancer cells and enhancing the effects of drugs like enzalutamide. They also disrupt the cancerâ€™s energy system, striking it on multiple fronts. This breakthrough could open a new path to overcoming drug resistance in advanced prostate cancer.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251110021056.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>Scientists find brain cells that could stop Alzheimerâ€™s</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers have identified special immune cells in the brain that help slow Alzheimerâ€™s. These microglia work to reduce inflammation and block the spread of harmful proteins. They appear to protect memory and brain health, offering a promising new direction for therapy.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251108083902.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>COVID vaccine linked to fewer infections and allergies in kids with eczema</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼švaccine<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šNew research suggests the COVID-19 vaccine could help children with eczema stay healthier overall. Vaccinated kids had lower rates of infections and allergies, including asthma and rhinitis, compared with unvaccinated peers. Experts believe the vaccine may help prevent allergic conditions from worsening, showing its value beyond protection from COVID-19.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251108012853.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>The hidden â€œBig Bangâ€ that decides how bowel cancer grows</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists have pinpointed a â€œBig Bangâ€ moment in bowel cancerâ€”when cells first evade the immune system. This early immune escape locks in how the cancer will behave as it grows. The discovery could help predict which patients respond to immunotherapy and lead to new vaccine strategies<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251107010250.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 2 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-åšå®¢æ›´æ–°">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>è‚¿ç˜¤</td>
<td>15</td>
</tr>
<tr>
<td>å…ç–«</td>
<td>15</td>
</tr>
<tr>
<td>å•ç»†èƒ</td>
<td>11</td>
</tr>
<tr>
<td>ç™Œç—‡</td>
<td>9</td>
</tr>
<tr>
<td>ä»£è°¢</td>
<td>9</td>
</tr>
<tr>
<td>leukemia</td>
<td>9</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>8</td>
</tr>
<tr>
<td>ç”Ÿä¿¡</td>
<td>7</td>
</tr>
<tr>
<td>cancer</td>
<td>6</td>
</tr>
<tr>
<td>è›‹ç™½è´¨ç»„</td>
<td>6</td>
</tr>
<tr>
<td>è½¬å½•ç»„</td>
<td>3</td>
</tr>
<tr>
<td>immune</td>
<td>3</td>
</tr>
<tr>
<td>Alzheimer</td>
<td>3</td>
</tr>
<tr>
<td>å…ç–«å¾®ç¯å¢ƒ</td>
<td>2</td>
</tr>
<tr>
<td>åŸºå› ç»„</td>
<td>2</td>
</tr>
<tr>
<td>æµ‹åº</td>
<td>2</td>
</tr>
<tr>
<td>resistance</td>
<td>2</td>
</tr>
<tr>
<td>ç»„è›‹ç™½</td>
<td>2</td>
</tr>
<tr>
<td>ç©ºé—´ç»„å­¦</td>
<td>2</td>
</tr>
<tr>
<td>ç–«è‹—</td>
<td>2</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (41æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MDk1NTY5MA==&amp;mid=2247540945&amp;idx=1&amp;sn=7f976c3b646e06f483d66c07e08c10e3" target="_blank" rel="noopener noreferrer">ã€ç½‘ç»œç ”è®¨ä¼šã€‘åˆ©ç”¨å•ç»†èƒä¸ç©ºé—´å¤šç»„å­¦æ¢ç´¢å¾®ç”Ÿç‰©ç»„ä¸å…ç–«äº’ä½œæœºåˆ¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503943&amp;idx=6&amp;sn=172af37f98d4551cd59ffaf0c05ffb4d" target="_blank" rel="noopener noreferrer">æœ€æ–°7.9åˆ†ç”Ÿä¿¡ï¼Œèšç„¦æ°¨åŸºé…¸ä»£è°¢çƒ­ç‚¹ï¼Œåˆ†æä¸å¤šï¼Œå®éªŒä¹Ÿåªæœ‰PCRã€‚é€‚åˆçŸ­å¹³å¿«å‘æ–‡ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247505925&amp;idx=1&amp;sn=9ae3348ff1e2b73ac3181182ba4fff29" target="_blank" rel="noopener noreferrer">CellÂ |Â æ¨Šå˜‰/å­£å½¤/å‘¨ä¿­/å­™äº‘å¸†/å¼ é™ˆå¹³åˆä½œæ­ç¤ºè‚¿ç˜¤åˆ©ç”¨ç¥ç»ä»‹å¯¼çš„è·¨å™¨å®˜é€šè®¯å®ç°å…ç–«é€ƒé€¸</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247506562&amp;idx=3&amp;sn=4f83ef7ea3583426dee4d03a3f9e93b6" target="_blank" rel="noopener noreferrer">Natureç»¼è¿°ï¼é“æ­»äº¡ä¸è‚¿ç˜¤å…ç–«æ²»ç–—</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247506562&amp;idx=2&amp;sn=0a30eefe918402989e6c3459684d00e2" target="_blank" rel="noopener noreferrer">Science | äººç±»æ³›ç–¾ç—…è¡€æ¶²è›‹ç™½è´¨ç»„å›¾è°±ï¼šå¾ªç¯è›‹ç™½è´¨ç»„çš„å…¨æ™¯è§£æä¸ç²¾å‡†åŒ»å­¦åº”ç”¨</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568174&amp;idx=1&amp;sn=918f0474afe65550b9a52e83a8a2a2bb" target="_blank" rel="noopener noreferrer">ã€Šè‡ªç„¶ã€‹ï¼šæœ‰æœ›å®Œå…¨æ¸…é™¤è‚¿ç˜¤ï¼è¿™ç§é¥®é£Ÿæ¨¡å¼ä¸è¯ç‰©è”ç”¨ï¼Œè®©è‡´å‘½ç™Œç—‡â€œæ”¹é‚ªå½’æ­£â€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568238&amp;idx=1&amp;sn=220ceb52eff7305b26b9646b145184ae" target="_blank" rel="noopener noreferrer">ã€Šè‡ªç„¶ã€‹é‡ç£…ï¼šä¸‰å¹´ç”Ÿå­˜ç‡æ¥è¿‘ç¿»å€ï¼æ²»ç–—ç™Œç—‡çš„ç–«è‹—å·²ç»å‡ºç°äº†ï¼Ÿ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&amp;mid=2247657847&amp;idx=2&amp;sn=547be09ce30923ea53fb5555005918c4" target="_blank" rel="noopener noreferrer">Cell: è‚ -è„‘è½´ä¿¡å·é€šè·¯é™åˆ¶åˆ†è§£ä»£è°¢æ¢å¤æœŸçš„è†³é£Ÿè›‹ç™½æ‘„å…¥ | Cell Pressè®ºæ–‡é€Ÿé€’</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxMjE4NDc2Mw==&amp;mid=2247502978&amp;idx=1&amp;sn=fd491753798bd5da131fb56783372df3" target="_blank" rel="noopener noreferrer">é€šè·¯å¯Œé›†ç»“æœå±•ç¤ºä¸å†åƒç¯‡ä¸€å¾‹</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkwODUyOTYzMw==&amp;mid=2247488609&amp;idx=1&amp;sn=c2954eb09c3865a3f16d87047111a3ae" target="_blank" rel="noopener noreferrer">ç”Ÿä¿¡å®ç”¨æŠ€èƒ½ç›˜ç‚¹ | md5sum</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzYyNDMwNjg3Nw==&amp;mid=2247484032&amp;idx=1&amp;sn=9b8ad353c3c456831fddf5206f967956" target="_blank" rel="noopener noreferrer">è¯¦è§£ï¼š2å‹ç³–å°¿ç—…çš„ä»£è°¢æœºåˆ¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&amp;mid=2247498467&amp;idx=1&amp;sn=c7b200800464e088ecd561197473ee57" target="_blank" rel="noopener noreferrer">å…¨åŸºå› ç»„ç»“æ„å˜å¼‚æ£€æµ‹æœ‰å›°éš¾ï¼ŸSyRIå¸®ä½ é€šé€šæå®šï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503943&amp;idx=2&amp;sn=86fa16db8c4425cd73411a193ab9870e" target="_blank" rel="noopener noreferrer">æ°¨åŸºé…¸ä»£è°¢æ˜¯çœŸçš„ç«ï¼Œå¹²æ¹¿ç»“åˆè½»æ¾å‘7.5åˆ†2åŒºæ–‡ç« ã€‚ç°åœ¨ä¸‹æ‰‹è¿˜ä¸æ™šï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&amp;mid=2247546875&amp;idx=1&amp;sn=692f800c63d56b43e257250562ec0866" target="_blank" rel="noopener noreferrer">pythonå•ç»†èƒå­¦ä¹ ï¼ˆäºŒï¼‰ï¼šä½¿ç”¨pythonæ‰¹é‡åŠ é€Ÿè¯»å–countçŸ©é˜µ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247505754&amp;idx=2&amp;sn=ca3489ef70749e73032271d660a87030" target="_blank" rel="noopener noreferrer">STTTï½œæå°/åˆ˜èŠåå›¢é˜Ÿç»˜åˆ¶é£Ÿç®¡é³ç™Œå…ç–«ç”Ÿæ€ç³»ç»Ÿå…¨æ™¯å›¾è°±ï¼Œæ­ç¤ºç”Ÿç‰©æ ‡å¿—ç‰©å’Œæ²»ç–—æ–°é¶ç‚¹</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247506054&amp;idx=2&amp;sn=6a5ef65a21c32cc59dcb12195d0f5416" target="_blank" rel="noopener noreferrer">Cell | éƒ­å¤©å—å›¢é˜Ÿç»˜åˆ¶è›‹ç™½è´¨é™åˆ¶é‡ç¼–ç¨‹å°é¼ è¡°è€çš„å¤šå™¨å®˜è›‹ç™½ç»„æ™¯è§‚</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247506355&amp;idx=1&amp;sn=265b7087371d2b3a3ded6d9104889272" target="_blank" rel="noopener noreferrer">Cell Discoveryï½œÏ€-HuB æ•°æ®å·¥å‚å¼€å¯æ— äººåŒ–è›‹ç™½è´¨ç»„å­¦æ•°æ®ç”Ÿäº§æ–°çºªå…ƒ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247506401&amp;idx=1&amp;sn=1635f84a177205fd1bec1035b41c3b42" target="_blank" rel="noopener noreferrer">æ–‡çŒ®é€Ÿé€’âˆ£è›‹ç™½è´¨ç»„å­¦ç ”ç©¶åŠ¨æ€ï¼ˆåæœˆï¼‰</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247506556&amp;idx=2&amp;sn=9f7e4dff0f231ea6d73cedd64a733838" target="_blank" rel="noopener noreferrer">è¡Œè·¯éš¾ï¼è¡Œè·¯éš¾ï¼å¤šæ­§è·¯ï¼Œä»Šå®‰åœ¨ï¼Ÿâ€”â€”èƒšèƒå‘è‚²å™¨å®˜å‘ç”Ÿå•ç»†èƒç»„å­¦æ•°æ®åº“OrganogenesisDBçš„ç ”ç©¶å†ç¨‹å›é¡¾</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247506556&amp;idx=1&amp;sn=1c87aa5de1eb14d8f40d2734f193d90e" target="_blank" rel="noopener noreferrer">è›‹ç™½è´¨ç»„å­¦ä¸´åºŠè½¬åŒ–åŒçªç ´ï¼šä¸¤å¤§è¯•å‰‚ç›’è·æ‰¹å¼•é¢†ç²¾å‡†è¯Šç–—æ–°æ—¶ä»£</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247506573&amp;idx=2&amp;sn=ba75cdac2d05f2816bad4fe1a988d872" target="_blank" rel="noopener noreferrer">Nature | å¤šç»„å­¦è§£æè¡°è€çš„å…ç–«</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247506623&amp;idx=3&amp;sn=ebea764be2e28cb2e3b6a999bbb5114f" target="_blank" rel="noopener noreferrer">Natureï¼šå…¨çƒç™Œç—‡ç»†èƒç–—æ³•ä¸´åºŠè¶‹åŠ¿</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247506980&amp;idx=1&amp;sn=1df98fee111d6706314a824ab90c546b" target="_blank" rel="noopener noreferrer">æ›²é™/åˆ˜å…‰æ…§/å¼ ç»´ç»®æ­ç¤ºæ ¸çº¤å±‚è›‹ç™½â€œå»ºç­‘å¸ˆâ€é€šè¿‡â€œå†…å¤–å…¼ä¿®â€æ„ç­‘ä¸‰ç»´åŸºå› ç»„ç»“æ„</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507020&amp;idx=2&amp;sn=12108ad369ad1f76d099624a94062611" target="_blank" rel="noopener noreferrer">Nature | GWASä¸è´Ÿè·æµ‹è¯•ï¼šæ®Šé€”ä¸ºä½•ä¸åŒå½’ï¼Ÿè§£å¯†åŸºå› å…³è”ç ”ç©¶ä¸­çš„æ’åºä¹‹è°œ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507070&amp;idx=3&amp;sn=909d2ce3e9bdb62e333c3c57a73b2c60" target="_blank" rel="noopener noreferrer">èƒŒé èƒŒNature | è§¦å‘â€œå¤è€â€çš„æ­»äº¡ï¼ŒæŠ‘åˆ¶æ¶æ€§çš„è‚¿ç˜¤</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkyNDI1MzE0NA==&amp;mid=2247490127&amp;idx=1&amp;sn=a4a338b0a2381d97d33083acde300cb4" target="_blank" rel="noopener noreferrer">å•ç»†èƒåˆ†è¾¨ç‡çš„è¡¨è¾¾å’Œå˜å¼‚è”åˆåˆ†æ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568179&amp;idx=2&amp;sn=4080da1a140929e7a8790f5672222af5" target="_blank" rel="noopener noreferrer">NEJMï¼šæ™šæœŸæˆ–è½¬ç§»æ€§è‚ºç™Œæ‚£è€…ç¼“è§£ç‡é«˜è¾¾71%ï¼é¶å‘æ–°è¯æ˜¾ç¤ºæŒä¹…æŠ—è‚¿ç˜¤æ´»æ€§</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568179&amp;idx=1&amp;sn=4a8d95afd8e59068c65f4649de00e8f7" target="_blank" rel="noopener noreferrer">ã€Šè‡ªç„¶ã€‹å­åˆŠï¼šä¸­å›½ç§‘å­¦å®¶æ­å¼€è‚ç™Œè½¬ç§»æ–°æœºåˆ¶ï¼è¿™äº›ç»†èƒå˜èº«è‚¿ç˜¤çš„â€œèƒ½é‡å·¥å‚â€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568303&amp;idx=1&amp;sn=af81a0e257c2ea1268314f3f262625c9" target="_blank" rel="noopener noreferrer">æ–°æ™‹è¯ºå¥–å¾—ä¸»æœ€æ–°è®ºæ–‡ï¼ä¸ºç‰¹æ®Šå…ç–«ç–¾ç—…å¸¦æ¥æ²»ç–—å¸Œæœ›</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568418&amp;idx=1&amp;sn=c0d281a302fb7312fef85659c83e05a3" target="_blank" rel="noopener noreferrer">èƒ½æ´»ä¸¤ç™¾å²ï¼Œä¸”å‡ ä¹ä¸å¾—ç™Œç—‡ï¼ã€Šè‡ªç„¶ã€‹ï¼šå®ƒä»¬å¥åº·é•¿å¯¿çš„å…³é”®æœºåˆ¶æ‰¾åˆ°äº†</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568513&amp;idx=2&amp;sn=7641c217c6ac8bbe11fa4bfcf9479b4e" target="_blank" rel="noopener noreferrer">â€œç™Œç—‡ä¹‹ç‹â€ç–¾ç—…æ§åˆ¶ç‡è¾¾100%ï¼ä¸Šç™¾æ¬¾æ–°è¯åœ¨ç ”ï¼Œä¸ºæ‚£è€…å¸¦æ¥æ–°æ›™å…‰</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568569&amp;idx=1&amp;sn=e49c800cd443673e364fbfb601f2315d" target="_blank" rel="noopener noreferrer">æ— è¿›å±•ç”Ÿå­˜æœŸç¿»å€ï¼é¢å¯¹æœ€è‡´å‘½çš„ç™Œç—‡ä¹‹ä¸€ï¼Œè¿™äº›ç–—æ³•æ­£åœ¨ç‚¹äº®æ²»ç–—ä¹‹å…‰</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568620&amp;idx=2&amp;sn=6bc01ce0780af268efb127730fb64603" target="_blank" rel="noopener noreferrer">è¿‘80%è‚¿ç˜¤è¢«æŠ‘åˆ¶ï¼é¶å‘ç™Œç»†èƒâ€œå¸®å‡¶â€ï¼Œæ–°ç–—æ³•æœ‰æœ›è®©å†·è‚¿ç˜¤è¿æ¥æ²»ç–—è½¬æœº</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568705&amp;idx=1&amp;sn=a9e3552e014e0e45aadc77d1890600d3" target="_blank" rel="noopener noreferrer">ç”Ÿå­˜ç‡å¯è¾¾90%ä»¥ä¸Šï¼è·¨è¶ŠåŠä¸ªä¸–çºªçš„æŠ—ç™Œæ¥åŠ›ï¼Œæ”¹å†™å…¨çƒå¥³æ€§æœ€å¸¸è§ç™Œç—‡çš„æ²»ç–—æ ¼å±€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568770&amp;idx=1&amp;sn=eeb6a54ff35088033b32d7c076ded9b4" target="_blank" rel="noopener noreferrer">ã€Šè‡ªç„¶ã€‹ï¼šè‚¿ç˜¤ç¼©å°è¶…80%ï¼é˜»æ–­è¿™ä¸ªè›‹ç™½ï¼Œè®©ç™Œç»†èƒâ€œè‡ªæˆ‘æ¯ç­â€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656509583&amp;idx=2&amp;sn=992822d3a6cae39dfabf804970dd5a0e" target="_blank" rel="noopener noreferrer">æ´è§Â·æ¢æœº|å¤–æ³Œä½“ä¸å¤–å‘¨å…ç–«ï¼Œå¼•é¢†å›½è‡ªç„¶ç”³æŠ¥æ–°èµ›é“</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656509583&amp;idx=1&amp;sn=18dcd522fcff473ac99ff03c129b94c1" target="_blank" rel="noopener noreferrer">èƒ¡å¿—æ–Œæ•™æˆé¢†è¡”ï¼æ­ç¤ºæ¯ä½“èƒ†å›ºé†‡æ°´å¹³è°ƒæ§èƒå„¿å¿ƒè„å‘è‚²æœºåˆ¶ï¼Œé¥®é£Ÿå¹²é¢„æˆ–æˆé¢„é˜²å…ˆå¤©æ€§å¿ƒè„ç—…æ–°ç­–ç•¥</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247649875&amp;idx=3&amp;sn=3883964cee1ba69740a8ddf851223a03" target="_blank" rel="noopener noreferrer">Cell Stem Cellï¼šæ›¾å®‰ç»„åˆä½œæ­ç¤ºå¿ƒè„å†ç”Ÿå…³é”®ç»†èƒ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247649875&amp;idx=1&amp;sn=b6fc666d4045a581232a52a663a4bb48" target="_blank" rel="noopener noreferrer">è¯ºå¥–é¢†èˆªï¼ä¸­å±±å¤§å­¦ã€å±±ä¸œå¤§å­¦ã€æ¸…åå¤§å­¦ã€å››å·å¤§å­¦ç­‰å›¢é˜Ÿçªç ´æ€§è¿›å±•ï¼Œè§£æå›½è‡ªç„¶å…ç–«çƒ­ç‚¹</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2MDY1NTYyOQ==&amp;mid=2247498876&amp;idx=1&amp;sn=97704b03e2e4047e889001b38ca2a155" target="_blank" rel="noopener noreferrer">è„šæœ¬æ›´æ–°--é«˜ç²¾åº¦ç©ºè½¬ï¼ˆXeniumã€CoxMxã€HDï¼‰ç©ºé—´é‚»åŸŸä¸å·®å¼‚è¡¨è¾¾åˆ†æ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU5OTgxNzU3NQ==&amp;mid=2247558411&amp;idx=1&amp;sn=148613e1869ea989a66b8365e5b42242" target="_blank" rel="noopener noreferrer">é‡ç£…è¿”åœºï¼åŸä½è‚¿ç˜¤æ¨¡å‹æ„å»ºå®è®­ç­å³å°†å†æ¬¡å¯åŠ¨ï¼</a></li>
</ul>
</div>
</details>

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (13æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255608" target="_blank" rel="noopener noreferrer">GSE255608 å®šåˆ¶åŸºäº CRISPR/Cas çš„è¡¨è§‚åŸºå› ç»„ç¼–è¾‘å™¨ä»¥å®ç°å¯ç¼–ç¨‹æŸ“è‰²è´¨é…°åŒ–å’Œé™ä½ç»†èƒæ¯’æ€§ [æ‰°åŠ¨æµ‹åº]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228081" target="_blank" rel="noopener noreferrer">GSE228081 å°åˆ†å­L-2-ç¾ŸåŸºæˆŠäºŒé…¸å¯¹è‚¾ç™Œä¸­mRNA m6Açš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280039" target="_blank" rel="noopener noreferrer">GSE280039 METTL3 dependent m6A RNA methylation is required for self-renewal and cell identity maintenance of human trophoblast stem cells</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271858" target="_blank" rel="noopener noreferrer">GSE271858 Phase separation mediates AKAP95 regulating oncogenic MLL-fusion driven transcription and its application in leukemia therapy</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271856" target="_blank" rel="noopener noreferrer">GSE271856 Phase separation mediates AKAP95 regulating oncogenic MLL-fusion driven transcription and its application in leukemia therapy (PRO-Seq)</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271855" target="_blank" rel="noopener noreferrer">GSE271855 Phase separation mediates AKAP95 regulating oncogenic MLL-fusion driven transcription and its application in leukemia therapy (CLIP-Seq)</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303815" target="_blank" rel="noopener noreferrer">GSE303815 è§£è€¦è¯ç‰©å’Œå¾®ç”Ÿç‰©ç¾¤å¯¹åŒ–ç–—å¼•èµ·çš„è‚ é“æ¯’æ€§çš„è´¡çŒ® [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297919" target="_blank" rel="noopener noreferrer">GSE297919 NSUN7 æ˜¯ä¸€ç§ RNA:m5C å‚¬åŒ–å¤±æ´»è›‹ç™½ï¼Œå¯è°ƒæ§ç²¾å­é­æ¯›ç»„è£… [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296011" target="_blank" rel="noopener noreferrer">GSE296011 è¡¥å……çŸ­é“¾è„‚è‚ªé…¸å’Œç›Šç”Ÿå…ƒå¯æ”¹å–„å¸•é‡‘æ£®ç—…æ‚£è€…çš„ä¸´åºŠç»“æœï¼šä¸€é¡¹éšæœºåŒç›²å‰ç»æ€§ç ”ç©¶ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281686" target="_blank" rel="noopener noreferrer">GSE281686 C57BL6/j å’Œ 129S1/SvImJ å°é¼ ç™½è‰²è„‚è‚ªç»„ç»‡ä¸­çš„è½¬å½•å› å­å ä½å—é—ä¼ å˜å¼‚çš„å½±å“ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281685" target="_blank" rel="noopener noreferrer">GSE281685 C57BL6/j å’Œ 129S1/SvImJ å°é¼ ç™½è‰²è„‚è‚ªç»„ç»‡ä¸­çš„è½¬å½•å› å­å ä½å—é—ä¼ å˜å¼‚çš„å½±å“ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE218452" target="_blank" rel="noopener noreferrer">GSE218452 åˆ©ç”¨RNA-Seqæ¢ç´¢INHBAåœ¨æ¹–ç¾Šé¢—ç²’ç»†èƒä¸­çš„ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217909" target="_blank" rel="noopener noreferrer">GSE217909 åœ¨è‘¡è„ç³–æˆ–å¾®æ™¶çº¤ç»´ç´ åŸ¹å…»æ¡ä»¶ä¸‹ï¼Œè‰é…¸é’éœ‰ä¸­ PoxCxrE åŸºå› ç¼ºå¤±å¯¼è‡´çš„å…¨åŸºå› ç»„åŸºå› è¡¨è¾¾æ”¹å˜</a></li>
</ul>
</div>
</details>

<details>
<summary><a name="æ›´å¤š-åšå®¢æ›´æ–°"></a>ğŸ§ª åšå®¢æ›´æ–° å…¶ä»–å†…å®¹ (2æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="https://www.sciencedaily.com/releases/2025/11/251106213557.htm" target="_blank" rel="noopener noreferrer">Mini llama proteins show promise for Alzheimerâ€™s treatment</a></li>
<li><a href="https://www.sciencedaily.com/releases/2025/11/251111010008.htm" target="_blank" rel="noopener noreferrer">åœ°çƒä¸Šæœ€ç¨€æœ‰çš„å…ƒç´ æˆ–å°†å½»åº•æ”¹å˜ç™Œç—‡æ²»ç–—ã€‚</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-13 00:30</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>